CD1C and neoplasm: Further understanding of the lipidome of malignant leukemic cells and identification of tumour specific lipid antigens will allow to develop lipid-specific TCR-based T cell engagers a new class of off-the shelf immunotherapeutic for CD1c positive leukemias.